Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

Launched by THE CLEVELAND CLINIC · Jul 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether temporarily stopping certain diabetes medications, called incretin-based therapies, before certain types of endoscopic procedures (like upper endoscopy) can help improve the examination process. The main goal is to see if holding these medications leads to less leftover food and liquid in the stomach, which can make it harder for doctors to perform the procedure safely and effectively. By understanding the impact of these medications on stomach contents, the trial aims to reduce complications during endoscopy.

To participate in this trial, you need to be an adult who has been on a stable dose of incretin-based therapy for at least one month and is scheduled for an outpatient endoscopic procedure. However, if you have certain conditions, like a history of delayed stomach emptying (gastroparesis) or have had specific surgeries affecting your stomach, you might not be eligible. Participants can expect to follow standard preparation guidelines before the procedure and may help improve care for others undergoing similar treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients using incretin-based therapies at a stable dose for more than 1 month.
• • Patients scheduled for outpatient esophagogastroduodenoscopy (EGD), endoscopic ultrasound (EUS), or endoscopic retrograde cholangiopancreatography (ERCP) under monitored anesthesia care.
• Exclusion Criteria:
• • Documented history of gastroparesis (based on a 4-hour solid-phase gastric emptying study)
• • Known history of achalasia
• • Surgical or genetically altered foregut anatomy
• • Known gastric outlet obstruction or pre-procedure imaging suggestive of gastric outlet obstruction.
• • Patients who did not follow the standard NPO (nil per oral) instructions.